ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus

Alkermes is not known as a cancer player, but still made waves at last year’s Esmo meeting with intriguing data for its IL-2 fusion protein nemvaleukin alfa. However, results presented at Asco today show a dwindling response rate in melanoma patients receiving nemva monotherapy.